1. Home
  2. FEED vs PULM Comparison

FEED vs PULM Comparison

Compare FEED & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEED

ENvue Medical Inc. Common Stock

N/A

Current Price

$0.66

Market Cap

5.6M

Sector

N/A

ML Signal

N/A

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$1.46

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEED
PULM
Founded
2003
2003
Country
United States
United States
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.1M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FEED
PULM
Price
$0.66
$1.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
595.7K
24.5K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$7,910,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5069.93
52 Week Low
$0.63
$1.16
52 Week High
$6.09
$9.00

Technical Indicators

Market Signals
Indicator
FEED
PULM
Relative Strength Index (RSI) 27.04 59.18
Support Level N/A $1.21
Resistance Level $0.97 $1.55
Average True Range (ATR) 0.09 0.10
MACD 0.00 0.02
Stochastic Oscillator 5.94 68.57

Price Performance

Historical Comparison
FEED
PULM

About FEED ENvue Medical Inc. Common Stock

ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: